MDMA-Assisted Therapy combines regulated doses of MDMA with psychotherapy to enhance the therapeutic process and help people reach memories, emotions, and insights that are not easily accessible.
The Multidisciplinary Association for Psychedelic Studies (MAPS) final Phase 3 MDMA-assisted therapy trial investigating the treatment of moderate to severe Post-Traumatic Stress Disorder (PTSD), showed promising results. 71.2% of participants who received MDMA-Assisted Therapy no longer met the criteria for PTSD, by the end of the study.
MDMA-Assisted Therapy is not currently an approved treatment, however, those with serious to life-threatening conditions may be able to gain approval through Canada’s Special Access Program on the grounds of compassionate access. If you believe you may qualify for this program, we can assist you in your application. To learn more, book a free informational call with one of our health navigators.
Clinical trial results indicate that MDMA-Assisted Therapy could be a promising treatment for Post-Traumatic Stress Disorder (PTSD).
MDMA has profound impacts on state of consciousness, creating empathy and openness that many people find to be a positive experience. MDMA can alter one’s perceptions and reduce feelings of depression, anxiety, and fear. Research suggests that by reducing fear and defensiveness, both of which are feelings often present in PTSD, MDMA can create a psychological state that is uniquely positioned to support long-term psychological healing from trauma.
Psychedelics are an emerging area of medicine. Information on this page is presented for educational purposes only and is not an exhaustive summary of the current state of research relative to psychedelic treatments, their reliability, contraindications, risks, side effects, or other pertinent information. Other than Spravato,® a form of esketamine, psychedelic medications have not been approved by Health Canada or the Food and Drug Administration for any mental health indication. Please refer to our Educational and Opinion Disclaimer.